Dr. James Ritchie

Title

Clinical Research Fellow – Center for Epidemiology, Institute of Population Health.

Role

Dr. Ritchie is a specialty trainee in nephrology who is undertaking research within the Center for Epidemiology under the supervision of Professor Philip Kalra and Dr. Smeeta Sinha. His main program of research aims to better describe the effects of clinical presentation and medical therapy on prognosis in atherosclerotic renovascular disease. In addition to this he has interests in how novel analytical methodologies may increase the value of large-scale observational datasets.

Memberships

Renal Association (founder member of Renal Clinical Skills Research Forum)
American Society of Nephrology
Royal College of Physicians (Ed)

Research topics

High-risk clinical presentations in atherosclerotic renovascular disease (ARVD)
Improved methods to describe disease burden in ARVD
Predictive strategies to assess risk for progression to end-stage kidney disease in ARVD
Application of double robust regression to assess randomized trial results within observational data

Skills and knowledge

Analytical skills

Planning of data capture, data cleansing and statistical analysis. Advanced methodologies including probability of treatment weighting, penalized spline models and double robust regression.

Clinical trials experience

Grant writing, patient recruitment, data collection.

Collaborators

Local

Prof PA Kalra
Dr. S Sinha
Dr. D Green

External

Dr. R Foley (United States Renal Data System)
Dr. B Braam (University of Alberta)
Dr. F Kronenberg (University of Innsbruck)

Publications

2013

1. Green D, Ritchie J, New DI, Kalra PA. How Accurately Do Nephrologists Predict the Need for Dialysis within One Year? Nephron Clin Pract. 2013 Apr 24;122(3-4):102–6.
2. Ritchie J, Rainone F, Green D, Alderson H. Extreme Elevations in Blood Pressure and All-Cause Mortality in a Referred CKD Population: Results from the CRISIS Study. International Journal of Hypertension 2013.
3. Haller ST, Kalra PA, Ritchie J, Chrysochou TT, Brewster PP, He WW, et al. Effect of CD40 and sCD40L on Renal Function and Survival in Patients With Renal Artery Stenosis. Hypertension 2013 Mar 31;61(4):894–900.

2012

1. Green D, Panayotova R, Ritchie J, O’Riordan E, McDonald J. Lipid-lowering therapy in chronic kidney disease: is there a role for ezetimibe? J Ren Care. 2012 Aug 31;38(3):138–46.
2. Ritchie J, Green D, Kalra PA. Current views on the management of atherosclerotic renovascular disease. Ann. Med. 2012 Jun;44 Suppl 1:S98–S110.
3. Ritchie J, Smyth A, Tower C, Helbert M, Venning M, Garovic VD. Maternal deaths in women with lupus nephritis: a review of published evidence. Lupus. 2012 Feb;21(5):534–541.

2011

1. Ritchie J, Chrysochou C, Kalra PA. Contemporary management of atherosclerotic renovascular disease: before and after ASTRAL. Nephrology (Carlton). 2011 Jul;16(5):457–67.
2. Ritchie J, Kalra PA. ASTRAL and Beyond: Who is Appropriate to Consider for Renal Artery Revascularization? Vascular Disease Management 2011;8:E12–20.
3. Hindle P, Ritchie J, Griffiths G, Howd A. Use of early scanning in fistula formation for vascular access. J Vasc Access. 2011 Mar;12(2):127–9.

2009

1. Shaw SM, Chaggar P, Ritchie J, Shah MKH, Baynes AC, O’Neill N, et al. The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin. Transplantation. 2009 Mar 15;87(5):771–5.